MedPath

Clinical efficacy and immune mechanism of Bushen Yifei Decoction in the treatment of stable chronic obstructive pulmonary disease

Phase 1
Recruiting
Conditions
Chronic obstructive pulmonary disease
Registration Number
ITMCTR2000003760
Lead Sponsor
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) The patients who meet the criteria of moderate and severe COPD in western medicine and meet the deficiency of both lung and kidney syndrome in traditional Chinese medicine were screened out;
(2) The age of the patients ranged from 40 to 80 years old;
(3) Men and women are not limited;
(4) Did not take any traditional Chinese medicine within 30 days;
(5) Inform patients of the research information, so that patients get the right to know, and voluntarily sign the relevant documents.

Exclusion Criteria

(1) Diseases with airflow limitation caused by special reasons, such as silicosis, interstitial lung disease, lung tumor, etc;
(2) The patients with active pulmonary tuberculosis, bronchiectasis, asthma, pleural effusion, pneumothorax and pulmonary embolism disease;
(3) Patients with severe heart, liver and kidney diseases, of which severe kidney disease mainly refers to kidney transplantation and dialysis; liver disease mainly includes varicose bleeding, portal hypertension and liver cirrhosis; heart diseases mainly include acute myocardial infarction, etc;
(4) Dementia or weak or no cognitive ability;
(5) Patients with neurological diseases that affect respiratory function;
(6) Patients with drug allergy and patients undergoing other clinical trials.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total score of TCM syndrome index;Number of acute exacerbations;
Secondary Outcome Measures
NameTimeMethod
Pulmonary function;Clinical total effective rate;Serum inflammatory factors;
© Copyright 2025. All Rights Reserved by MedPath